ES2180784T3 - Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo. - Google Patents

Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo.

Info

Publication number
ES2180784T3
ES2180784T3 ES96919971T ES96919971T ES2180784T3 ES 2180784 T3 ES2180784 T3 ES 2180784T3 ES 96919971 T ES96919971 T ES 96919971T ES 96919971 T ES96919971 T ES 96919971T ES 2180784 T3 ES2180784 T3 ES 2180784T3
Authority
ES
Spain
Prior art keywords
compositions
circulation
mixed micelles
blood
mri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919971T
Other languages
English (en)
Inventor
Herve Tournier
Bernard Lamy
Roland Hyacinthe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Research SA
Original Assignee
Bracco Research SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Research SA filed Critical Bracco Research SA
Application granted granted Critical
Publication of ES2180784T3 publication Critical patent/ES2180784T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES DE CONTRASTE DE FORMACION DE IMAGENES POR NMR QUE CONTIENEN ESPECIES QUE RESPONDEN MAGNETICAMENTE UNIDAS A MATERIALES DE BASE ORGANICOS ANFIPATICOS FISIOLOGICAMENTE ACEPTABLES A MODO DE MICELAS MIXTAS SUSPENDIDAS O DISPERSADAS EN UN SOPORTE LIQUIDO ACUOSO FISIOLOGICAMENTE ACEPTABLE. LAS COMPOSICIONES SON PARTICULARMENTE UTILES PARA INVESTIGACIONES DE DIAGNOSTICO DE BOLSAS DE SANGRE. LA INVENCION TAMBIEN SE REFIERE A LA PREPARACION DE LAS MICELAS MIXTAS, ASI COMO A COMPOSICIONES INYECTABLES QUE CONTIENEN LAS MICELAS MIXTAS COMO AGENTES DE CONTRASTE PARA MRI. UNA VEZ INYECTADAS, LAS MICELAS MIXTAS DE LAS COMPOSICIONES SE COMPORTAN COMO INTENSIFICADORES DEL CONTRASTE PARA LA FORMACION DE IMAGENES, EJ. MEJORARAN LA CALIDAD Y LA RESOLUCION DE LAS IMAGENES PROCESADAS ELECTRONICAMENTE OBTENIDAS DURANTE EXAMENES POR MRI DE LA CIRCULACION Y/O DE LOS ORGANOS DE LA CIRCULACION SELECCIONADOS. LAS COMPOSICIONES SE FORMULAN PARA PROTEGER A LAS PARTICULAS DE LOS AGENTES DE CONTRASTE CONTRA UNA RETIRADA ANTICIPADA POR PARTE DEL SISTEMA RETICULOENDOTELIAL (RES) DEL HIGADO Y DEL BAZO, DE MODO QUE PERMANEZCAN EN CIRCULACION DURANTE UN PERIODO DE TIEMPO SUFICIENTE COMO PARA PODER TOMAR UNA IMAGEN CORRECTA DE LOS VASOS SANGUINEOS Y SEAN TRANSPORTADOS A LOS ORGANOS SELECCIONADOS. LA FORMACION DE IMAGENES POR MRI DE LA CIRCULACION Y DE LOS ORGANOS SELECCIONADOS PUEDE AYUDAR EN GRAN MEDIDA EN EL DIAGNOSTICO DE POSIBLES SUFRIMIENTOS DE PACIENTES HUMANOS Y ANIMALES.
ES96919971T 1995-06-15 1996-06-14 Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo. Expired - Lifetime ES2180784T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95810403 1995-06-15

Publications (1)

Publication Number Publication Date
ES2180784T3 true ES2180784T3 (es) 2003-02-16

Family

ID=8221760

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919971T Expired - Lifetime ES2180784T3 (es) 1995-06-15 1996-06-14 Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo.

Country Status (13)

Country Link
US (1) US5833948A (es)
EP (1) EP0804251B1 (es)
JP (1) JP4335976B2 (es)
KR (1) KR100399712B1 (es)
AT (1) ATE224737T1 (es)
AU (1) AU708328B2 (es)
CA (1) CA2195633C (es)
DE (1) DE69623929T2 (es)
ES (1) ES2180784T3 (es)
NO (1) NO314127B1 (es)
PT (1) PT804251E (es)
WO (1) WO1997000087A1 (es)
ZA (1) ZA965101B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6342598B1 (en) 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
IT1304501B1 (it) * 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20060073197A1 (en) * 2004-05-20 2006-04-06 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US20070128253A1 (en) * 2005-04-13 2007-06-07 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
DE602004029010D1 (de) 2003-02-04 2010-10-21 Bracco Suisse Sa Ultraschall kontrastmittel und verfahren zur erstellung
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
US20050152842A1 (en) * 2003-12-24 2005-07-14 Chun Li Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent
DE602005010424D1 (de) * 2004-06-03 2008-11-27 Bracco Research Sa Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
JP4837663B2 (ja) 2004-08-18 2011-12-14 ブラッコ・シュイス・ソシエテ・アノニム 造影画像化のためのガス充填微小胞組成物
FR2883562B1 (fr) 2005-03-24 2009-02-27 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie
CA2603437A1 (en) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Poly(peptide) as a chelator: methods of manufacture and uses
WO2006128643A2 (en) * 2005-05-31 2006-12-07 Inbios S.R.L. Supramolecular aggregates containing chelating agents and bioactive peptides as effective and selective delivery tools for drugs and contrast agents in mri or nuclear medicine
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
DE602007006968D1 (de) 2006-09-05 2010-07-15 Bracco Research Sa Gasgefüllte mikrovesikel mit polymer-modifizierten lipiden
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20090074751A1 (en) * 2007-09-18 2009-03-19 Ramaekers Nutrition, Inc. Growth factor fraction compositions and methods
KR101401217B1 (ko) * 2007-11-07 2014-05-28 충남대학교산학협력단 Ｐｅ－ｄｔｐａ의 새로운 용도
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
EP2278984A4 (en) * 2007-11-30 2013-02-27 Ramaekers Family Trust COMPOSITIONS AND METHODS FOR ENHANCING FERTILITY
SG10201500237TA (en) 2008-01-30 2015-04-29 Histogen Inc Extracellular matrix compositions
WO2010094043A2 (en) 2009-02-13 2010-08-19 University Of Washington Gadolinium expressed lipid nanoparticles for magnetic resonance imaging
WO2010139003A1 (en) * 2009-06-01 2010-12-09 Commonwealth Scientific And Industrial Research Organisation Chelating amphiphiles
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
EP2892570B1 (en) 2012-09-07 2019-02-27 Bracco Imaging S.p.A Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
EP2934740B1 (en) 2012-12-21 2019-12-11 Bracco Suisse SA Gas-filled microvesicles
WO2015119642A1 (en) 2014-02-10 2015-08-13 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387410A (en) * 1983-03-18 1995-02-07 Mallinckrodt, Inc. Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
CA2102605A1 (en) * 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging

Also Published As

Publication number Publication date
CA2195633A1 (en) 1997-01-03
EP0804251A1 (en) 1997-11-05
DE69623929T2 (de) 2003-05-15
WO1997000087A1 (en) 1997-01-03
DE69623929D1 (de) 2002-10-31
JPH10504044A (ja) 1998-04-14
ATE224737T1 (de) 2002-10-15
JP4335976B2 (ja) 2009-09-30
KR100399712B1 (ko) 2004-02-18
CA2195633C (en) 2008-09-16
KR970704477A (ko) 1997-09-06
NO970665L (no) 1997-04-03
ZA965101B (en) 1997-01-22
PT804251E (pt) 2003-01-31
US5833948A (en) 1998-11-10
AU5843196A (en) 1997-01-15
NO314127B1 (no) 2003-02-03
AU708328B2 (en) 1999-08-05
NO970665D0 (no) 1997-02-13
EP0804251B1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
ES2180784T3 (es) Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo.
IL125895A0 (en) The use of an image enhancing moiety in the preparation of bioactivated nmr or optical imaging contrat agent from a prodrug
ES2152932T3 (es) Particulas de apatita tratadas para tecnicas de imagen para diagnostico medico.
EP0994352A3 (en) Contrast agent enhanced magnetic resonance imaging of myocardial tissue
Tournissac et al. Cranial window for longitudinal and multimodal imaging of the whole mouse cortex
Chin et al. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants
Sumiyoshi et al. Sexual differentiation of the adolescent rat brain: a longitudinal voxel-based morphometry study
Gorospe et al. Ewing’s sarcoma of the mandible: radiologic features with emphasis on magnetic resonance appearance
Halimi et al. Post-traumatic diabetes insipidus: MR demonstration of pituitary stalk rupture
US20190128785A1 (en) Compositions and methods for tissue clearing
NO964501L (no) Liposomsuspensjoner som blod-pool bildekontrastmidler
Ito et al. Development of agents for reinforcement of fluorescence on near-infrared ray excitation for immunohistological staining
Getzmann et al. Impact of acceleration on bone depiction quality by ultrashort echo time magnetic resonance bone imaging sequences in medication-related osteonecrosis of the jaw
Lutsep et al. Does reversal of ischemia on diffusion‐weighted imaging reflect higher apparent diffusion coefficient values?
Chhem Paleoradiology: history and new developments
Fujisawa et al. MR imaging findings in the posterior pituitary gland
Taori et al. Aneurysmal bone cyst of talus: a rare case
Sbarbati et al. Magnetic resonance imaging of the rat Harderian gland
Inzitari et al. Therapy of vascular dementias
Tavares et al. Magnetic resonance imaging perfusion technique in the evaluation of achilles tendon injury in rabbits
Gates et al. Neuroimaging of fractureless transforamen magnum penetrating injury of the cerebellum
Junior et al. Magnetic resonance imaging perfusion technique in the evaluation of achilles tendon injury in rabbits
Ravsten et al. Ex vivo Bio-orthogonal MRI imaging–A novel method proposed for metastatic cancer detection
Friedrich et al. Noninvasive diagnosis of acute myocarditis by contrast-enhanced magnetic resonance imaging
LODGE et al. Reproducibility of quantitative permeability measurements in dynamic contrast-enhanced MRI studies